MedTrace Logo

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2006-10-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether MC-1 is effective and safe in reducing cardiovascular and neurological events in patients undergoing high-risk coronary artery bypass surgery

Conditions

  • Coronary Artery Bypass Graft Surgery
  • Myocardial Ischemia
  • Reperfusion Injury
  • Myocardial Revascularization

Interventions

DRUG

(MC-1) Pyridoxal-5'-phosphate

Sponsors & Collaborators

  • Medicure

    lead INDUSTRY

Principal Investigators

  • Jean-Claude Tardif, MD, FRCPC, FACC · Montreal Heart Institute Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2005-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157716 on ClinicalTrials.gov